We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Read MoreHide Full Article
Key Takeaways
Day One Biopharmaceuticals to be acquired by Servier for $21.50 per share in a deal valued at about $2.5B.
DAWN stock jumped nearly 66% after the deal announcement.
The acquisition adds Ojemda and two early-stage ADC candidates to Servier's oncology portfolio.
Day One Biopharmaceuticals (DAWN - Free Report) has signed a definitive agreement with France-based Servier. Per the terms, Servier will acquire all outstanding shares of DAWN at $21.50 each, valuing the deal at about $2.5 billion.
Post this acquisition, Servier will add Ojemda — Day One Biopharmaceuticals’ first marketed drug, which was granted accelerated approval by the FDA in 2024 to treat relapsed or refractory pediatric low-grade glioma (pLGG), a form of brain tumor. The drug is currently being evaluated in the pivotal phase III FIREFLY-2 study in patients with frontline pLGG, which is expected to complete enrolment in the first half of 2026.
The deal is expected to close in the second quarter. Servier anticipates funding this transaction through existing cash and investments.
DAWN Stock Price Performance
Following this news, the company's shares surged nearly 66% on Friday.
Year to date, the stock has skyrocketed 127% compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
What’s Driving Servier’s Interest in DAWN?
The motivation behind the deal seems clear — the acquisition will support Servier’s 2030 ambition to develop innovative treatments across oncology, cardiometabolism, neuroscience and immuno-inflammation indications. Last month, Day One Pharmaceuticals reported Ojemda sales of $155.4 million for the full year 2025, up 172% year over year. Based on the encouraging sales potential, it guided the drug’s 2026 sales between $225 million and $250 million.
Apart from Ojemda, the DAWN acquisition will expand Servier’s oncology portfolio with two antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301. Both these therapies are being evaluated in separate early-stage studies, with data readouts expected later this year.
The DAWN acquisition adds to Servier’s list of deals in the oncology space over the last few years. Last year, it signed a global licensing deal with Black Diamond Therapeutics (BDTX - Free Report) for the latter’s BDTX-4933, an investigational therapy targeting RAF and RAS alterations in solid tumors. In September 2025, Servier signed a similar deal with Ideaya Biosciences (IDYA - Free Report) for the latter’s experimental rare eye cancer treatment, darovasertib.
View the Zacks #1 Rank List
Image: Bigstock
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Key Takeaways
Day One Biopharmaceuticals (DAWN - Free Report) has signed a definitive agreement with France-based Servier. Per the terms, Servier will acquire all outstanding shares of DAWN at $21.50 each, valuing the deal at about $2.5 billion.
Post this acquisition, Servier will add Ojemda — Day One Biopharmaceuticals’ first marketed drug, which was granted accelerated approval by the FDA in 2024 to treat relapsed or refractory pediatric low-grade glioma (pLGG), a form of brain tumor. The drug is currently being evaluated in the pivotal phase III FIREFLY-2 study in patients with frontline pLGG, which is expected to complete enrolment in the first half of 2026.
The deal is expected to close in the second quarter. Servier anticipates funding this transaction through existing cash and investments.
DAWN Stock Price Performance
Following this news, the company's shares surged nearly 66% on Friday.
Year to date, the stock has skyrocketed 127% compared with the industry’s 4% growth.
Image Source: Zacks Investment Research
What’s Driving Servier’s Interest in DAWN?
The motivation behind the deal seems clear — the acquisition will support Servier’s 2030 ambition to develop innovative treatments across oncology, cardiometabolism, neuroscience and immuno-inflammation indications. Last month, Day One Pharmaceuticals reported Ojemda sales of $155.4 million for the full year 2025, up 172% year over year. Based on the encouraging sales potential, it guided the drug’s 2026 sales between $225 million and $250 million.
Apart from Ojemda, the DAWN acquisition will expand Servier’s oncology portfolio with two antibody drug conjugate (ADC) candidates, emiltatug ledadotin (emi-le) and DAY301. Both these therapies are being evaluated in separate early-stage studies, with data readouts expected later this year.
The DAWN acquisition adds to Servier’s list of deals in the oncology space over the last few years. Last year, it signed a global licensing deal with Black Diamond Therapeutics (BDTX - Free Report) for the latter’s BDTX-4933, an investigational therapy targeting RAF and RAS alterations in solid tumors. In September 2025, Servier signed a similar deal with Ideaya Biosciences (IDYA - Free Report) for the latter’s experimental rare eye cancer treatment, darovasertib.
Day One Biopharmaceuticals, Inc. Price
Day One Biopharmaceuticals, Inc. price | Day One Biopharmaceuticals, Inc. Quote
DAWN Zacks Rank
Day One Biopharmaceuticals currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.